Encouraging first results with Altropane:
This article was originally published in Clinica
Promising results have been achieved in initial trials of Boston Life Sciences' Altropane with three healthy patients. The agent could be an accurate means of imaging the brain dopamine transporter system within one hour of injection, says Dr Marc Lanser, chief scientific officer of Boston Life Sciences (US). It is hoped that it will permit a precise, noninvasive diagnosis of Parkinson's disease (see Clinica 675, p 19).
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.